MARKET

CYTO

CYTO

Altamira Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7500
-0.0384
-4.87%
After Hours: 0.7500 0 0.00% 17:18 05/27 EDT
OPEN
0.7990
PREV CLOSE
0.7884
HIGH
0.8262
LOW
0.7400
VOLUME
215.72K
TURNOVER
0
52 WEEK HIGH
4.580
52 WEEK LOW
0.6208
MARKET CAP
11.45M
P/E (TTM)
-0.5264
1D
5D
1M
3M
1Y
5Y
Altamira gets Philippines FDA approval for Bentrio nasal spray
Altamira Therapeutics (NASDAQ:CYTO) stock rose ~5% after the company said that the Philippines' Food and Drug Administration (FDA) approved its Bentrio nasal spray, designed to protect against airborne viruses and allergens.
Seekingalpha · 5d ago
Altamira Therapeutics Receives Philippines' FDA Approval Of Bentrio Nasal Spray
  HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that
Benzinga · 5d ago
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio™ has been approved by the Philippines' Food an...
ACCESSWIRE · 5d ago
Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study
Benzinga · 05/20 15:24
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safetyHAMILTON, BERMUDA / ACCESSWIRE / May 20, 2022 / Altamira Therapeutics Ltd.
ACCESSWIRE · 05/20 13:00
Altamira Says Bentrio Nasal Spray Shows Positive Results in House Dust Mite Trial; Shares Rise
MT Newswires · 05/20 10:43
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022/ Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it is scheduled to present virtually at the H.
ACCESSWIRE · 05/19 13:00
Altamira Therapeutics Issues Shareholder Letter
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a
Benzinga · 05/18 12:51
More
No Data
Learn about the latest financial forecast of CYTO. Analyze the recent business situations of Altamira Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYTO stock price target is 14.04 with a high estimate of 14.04 and a low estimate of 14.04.
High14.04
Average14.04
Low14.04
Current 0.7500
EPS
Actual
Estimate
-8.13-6.10-4.06-2.03
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q4 2017
Institutional Holdings
Institutions: 25
Institutional Holdings: 1.48M
% Owned: 9.68%
Shares Outstanding: 15.26M
TypeInstitutionsShares
Increased
5
45.62K
New
3
18.56K
Decreased
5
55.47K
Sold Out
4
20.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Meyer
Non-Executive Vice Chairman
James Healy
Chief Financial Officer/Primary Contact
Hernan Levett
General Counsel
Anne Zoller
Other/IR Contact Officer
Cindy McGee
Other
Andrea Braun
Other
Thomas Jung
Other
Bettina Stubinski
Director
Mats Blom
Director
Alain Munoz
Non-Executive Independent Director
Oliver Kubli
Non-Executive Independent Director
Berndt Modig
Non-Executive Independent Director
Armando Anido
Non-Executive Independent Director
Calvin Roberts
Non-Executive Independent Director
Wolfgang Arnold
No Data
No Data
About CYTO
Auris Medical Holding AG is a Switzerland-based biotechnologyompany focused on developing and commercializing therapeutics and medical devices for neurotology, rhinology and allergy and central nervous system (CNS) disorders.The Company is active in active in three areas such as: the development of oligonucleotides for extrahepatic therapeutic targets - OligoPhore platform; nasal sprays for protection against airborne viruses and allergens Bentrio or the treatment of vertigo AM-125 ; he development of therapeutics for intratympanic treatment of tinnitus Keyzilen or hearing loss Sonsuvi .

Webull offers kinds of Altamira Therapeutics Ltd stock information, including NASDAQ:CYTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTO stock methods without spending real money on the virtual paper trading platform.